CCO Independent Conference Highlights of the Virtual 2021 Gastrointestinal (GI) Cancers Symposium
  • CME

January 15-17, 2021; Virtual Meeting
Review expert perspectives on the most clinically relevant data on gastrointestinal cancers presented at ASCO GI 2021.
Axel Grothey Headshot
Axel Grothey, MD
Manish A. Shah, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: March 10, 2021 Expiration: March 9, 2022

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with gastrointestinal cancers
  • Identify subpopulations of patients with gastrointestinal cancers most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Discuss new data on novel agents and therapeutic approaches for patients with gastrointestinal cancers
  • Consider how new trial findings might affect treatment of gastrointestinal cancers in the future

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Merck Sharp & Dohme Corp.
Seagen Inc.
Taiho Oncology Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Axel Grothey, MD

Director of GI Cancer Research
West Cancer Center and Research Institute
Germantown, Tennessee

Axel Grothey, MD, has disclosed that he has received consulting fees and funds for research support paid to his institution from Array/Pfizer, Bayer, Boston Biomedicals, Daiichi Sankyo, Ipsen, Medimmune, Merck, OBI Pharmaceuticals, and Roche/Genetech.
Manish A. Shah, MD

Bartlett Family Professor of Gastrointestinal Oncology
Chief,
Solid Tumor Services
Director, Gastrointestinal Oncology Program
Co-Director, Center for Advanced Digestive Care
Weill Cornell Medical College
NewYork-Presbyterian Hospital
New York, New York

Manish A. Shah, MD, has disclosed that he has received funds for research support from Astellas, Bristol-Myers Squibb, and Merck.

Staff

Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Kristen Morrow, PhD

Editorial Contributor

Kristen Morrow has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason J. Everly, PharmD, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with gastrointestinal cancers.

Goal

The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with gastrointestinal cancers.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 10, 2021, through March 09, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for gastroesophageal cancers

Manish A. Shah, MD Released: January 21, 2022

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and biliary tract cancers

Rachna Shroff, MD Released: January 21, 2022

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for colorectal cancer (CRC)

John L. Marshall, MD Released: January 21, 2022

In this video from Clinical Care Options (CCO), Drs Michael Bishop, Jesús Berdeja, and Jae Park discuss key data on CAR T-cell therapy

Michael R. Bishop, MD
Program Director
person default Jesús G. Berdeja, MD Jae H. Park, MD
Physicians: maximum of 2.25 AMA PRA Category 1 Credits Released: January 13, 2022 Expired: January 12, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings